12/5
06:30 am
zyme
Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.
Low
Report
Zymeworks (NASDAQ:ZYME) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.
12/3
09:11 am
zyme
Zymeworks (NYSE:ZYME) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $32.00 price target on the stock.
Medium
Report
Zymeworks (NYSE:ZYME) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $32.00 price target on the stock.
12/3
07:18 am
zyme
Zymeworks (NYSE:ZYME) was given a new $32.00 price target on by analysts at JMP Securities.
Medium
Report
Zymeworks (NYSE:ZYME) was given a new $32.00 price target on by analysts at JMP Securities.
12/3
06:04 am
zyme
Zymeworks (NYSE:ZYME) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Medium
Report
Zymeworks (NYSE:ZYME) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
12/2
04:05 pm
zyme
Zymeworks Announces Participation in Upcoming Conferences
Medium
Report
Zymeworks Announces Participation in Upcoming Conferences
11/29
07:17 am
zyme
Zymeworks (NASDAQ:ZYME) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Zymeworks (NASDAQ:ZYME) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/24
06:00 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Medium
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
11/21
09:13 am
zyme
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA [Seeking Alpha]
Low
Report
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA [Seeking Alpha]
11/21
09:10 am
zyme
Zymeworks (NYSE:ZYME) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Zymeworks (NYSE:ZYME) had its "buy" rating reaffirmed by analysts at B. Riley.
11/19
02:19 pm
zyme
Zymeworks: A Lot Of Moving Parts [Seeking Alpha]
Low
Report
Zymeworks: A Lot Of Moving Parts [Seeking Alpha]
11/19
09:43 am
zyme
Zymeworks (ZYME): Assessing Valuation After 60% Rally and Recent Earnings Momentum [Yahoo! Finance]
Low
Report
Zymeworks (ZYME): Assessing Valuation After 60% Rally and Recent Earnings Momentum [Yahoo! Finance]
11/19
07:00 am
zyme
Zymeworks (NYSE:ZYME) was given a new $40.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Zymeworks (NYSE:ZYME) was given a new $40.00 price target on by analysts at Stifel Nicolaus.
11/19
06:02 am
zyme
Zymeworks (NYSE:ZYME) had its "cautious" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Zymeworks (NYSE:ZYME) had its "cautious" rating reaffirmed by analysts at Wells Fargo & Company.
11/18
08:03 am
zyme
Zymeworks (NYSE:ZYME) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Zymeworks (NYSE:ZYME) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock.
11/18
01:39 am
zyme
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets [Yahoo! Finance]
Medium
Report
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets [Yahoo! Finance]
11/18
01:39 am
zyme
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer [Yahoo! Finance]
Medium
Report
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer [Yahoo! Finance]
11/18
01:01 am
zyme
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Medium
Report
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
11/18
01:00 am
zyme
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Medium
Report
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
11/17
05:04 pm
zyme
Zymeworks (NYSE:ZYME) was given a new $37.00 price target on by analysts at Leerink Partners.
Medium
Report
Zymeworks (NYSE:ZYME) was given a new $37.00 price target on by analysts at Leerink Partners.
11/17
08:43 am
zyme
Stocks making the biggest moves premarket: Alphabet, Zymeworks, lithium producers, Quantum Computing, Clearwater Analytics and more [CNBC]
Medium
Report
Stocks making the biggest moves premarket: Alphabet, Zymeworks, lithium producers, Quantum Computing, Clearwater Analytics and more [CNBC]
11/17
07:15 am
zyme
Jazz, Zymeworks' Ziihera trial shows significant PFS improvement, shares rally [Seeking Alpha]
Medium
Report
Jazz, Zymeworks' Ziihera trial shows significant PFS improvement, shares rally [Seeking Alpha]
11/17
06:13 am
zyme
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma [Yahoo!
High
Report
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma [Yahoo!
11/17
06:00 am
zyme
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
High
Report
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
11/9
07:03 pm
zyme
Zymeworks Inc. (NASDAQ:ZYME) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Medium
Report
Zymeworks Inc. (NASDAQ:ZYME) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]